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The identification of a beta-cell tracer is a major quest in diabetes research. However, since MRI, PET 
and SPECT cannot resolve individual islets, optical techniques are required to assess the specificity 
of these tracers. We propose to combine Optical Coherence Microscopy (OCM) with fluorescence 
detection in a single optical platform to facilitate these initial screening steps from cell culture up to 
living rodents. OCM can image islets and vascularization without any labeling. Thereby, it alleviates 
the need of both genetically modified mice to detect islets and injection of external dye to reveal 
vascularization. We characterized Cy5.5-exendin-3, an agonist of glucagon-like peptide 1 receptor 
(GLP1R), for which other imaging modalities have been used and can serve as a reference. Cultured 
cells transfected with GLP1R and incubated with Cy5.5-exendin-3 show full tracer internalization. We 
determined that a dose of 1 μ g of Cy5.5-exendin-3 is sufficient to optically detect in vivo the tracer in 
islets with a high specificity. In a next step, time-lapse OCM imaging was used to monitor the rapid 
and specific tracer accumulation in murine islets and its persistence over hours. This optical platform 
represents a versatile toolbox for selecting beta-cell specific markers for diabetes research and future 
clinical diagnosis.
Islets of Langerhans are structures hosting the insulin-producing beta-cells, which play a central role 
in glucose homeostasis. For a deeper understanding of the pathogenesis of diabetes and for developing 
beneficial treatments protecting beta-cells, improving their function or promoting their proliferation/
regeneration during diabetes, an accurate assessment of the beta-cell volume is necessary. These ambi-
tious goals motivate the search for specific beta-cell markers. The utmost goal is to achieve human in vivo 
imaging of beta cells, which is an on-going worldwide effort of intensive research1,2.
Non-invasive clinical imaging techniques such as MRI, PET or SPECT rely on contrast agents or 
radio-ligand tracers to discriminate between the endocrine and exocrine pancreas. However, these clin-
ical imaging modalities cannot provide a sufficient resolution to resolve individual islets, and therefore 
rely solely on the contrast quality of the used bio-tracer. Therefore, imaging of smaller individual islets 
requires the higher spatial resolution of optical imaging. Although optical imaging has a limited pen-
etration depth of a few hundred micrometers and therefore would have very limited use in a clinical 
setting, it can provide an alternative to assess the specificity of beta-cell markers in recognized animal 
models. In principle, classical optical techniques such as fluorescence microscopy, confocal3 or 2-photon 
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microscopy4 allow identifying fluorescently labelled beta-cell tracers. However, their voxel by voxel scan-
ning results in long imaging acquisition times, making in vivo imaging of the pancreas in the abdomi-
nal cavity and time-lapse imaging during the tracer accumulation challenging. Line-scanning confocal 
fluorescence imaging overcomes this speed limitation5 but similarly to other classical optical techniques 
requires genetically modified mice to visualize pancreatic islets6. Optical Coherence Microscopy (OCM) 
circumvents all these limitations by providing fast, three-dimensional label free imaging of islets of 
Langerhans7,8 along with the islet vascularization and blood flow9–11.
In this paper, we exploit the advantages of OCM enhanced with a confocal fluorescence channel to 
assess the specificity and the dynamics of a beta-cell tracer linked to a fluorophore. As a proof of prin-
ciple, we demonstrate the high beta-cell specificity of a Cy5.5-exendin-3 tracer in vitro and in vivo for 
which other imaging modalities have been used and can serve as reference. Exendin-3 is an agonist of 
the glucagon-like peptide-1 (GLP1) that targets glucagon-like peptide-1 receptor (GLP1R), a promising 
candidate due to the specificity and the high level of GLP1R expression on beta-cells12–14. Using GLP1 
agonists, promising results have been obtained with PET and SPECT15–20, MRI21,22 and fluorescence 
microscopy3,23,24. Our study reveals promising specificity and dynamic features of GLP1 tracers and sets 
a platform for further characterization of beta-cell tracers.
Results
Exendin-3 coupled to Cy5.5 retains efficient binding to GLP1R. The tracer exendin-3 has already 
been investigated with different modalities15,25. For an optical monitoring of the exendin-3 binding pro-
cess to cells expressing GLP1R in vivo, we coupled Cy5.5 to exendin-3 to the epsilon amino-group of the 
C-terminal lysine in analogy to the DTPA conjugated exendin. This strategy allows a straight comparison 
between the radiolabeled and fluorescently labeled compound. To investigate if this modification alters 
the pharmacological properties DTPA-exendin-3 was labeled with 111InC3 with a specific activity of 700 
GBq/μ mol. The radiochemical purity was 95% as determined by ITLC. Radiolabelled exendin-3 and 
Cy5.5-exendin-3 were used to determine the IC50 diagrams using Chinese hamster lung (CHL) cells 
stably expressing GLP1R. Both compounds showed a high affinity for the GLP1R. The idem IC50 values 
of exendin-3 and Cy5.5-exendin-3 were 2.6 nM and 10.8 nM respectively (Fig.  1 with 95% confidence 
intervals of 1.9–3.4 and 7.0–16.7 respectively). These values in the nanomolar range are not significantly 
different (p = 0.68).
Cy5.5-exendin-3 binding and internalization in vitro in cells expressing GLP1R. To assess the 
specificity of Cy5.5-exendin-3 for GLP1R, stably transfected CHL cells with the human GLP1R were 
used and imaged with dark field OCM (dfOCM). The novel instrument we designed (Fig. 2) combines 
OCM to detect islets or cells based on their natural scattering8 with fluorescence to detect the tested 
tracer. OCM part works in two configurations: extended focus OCM (xfOCM)26 and dark field OCM 
(dfOCM)27. xfOCM is optimized for small animal imaging whereas dfOCM possesses dark field contrast 
enhancement and is designed for cell imaging. dfOCM allows imaging of the weak scattering signal from 
cells by suppressing the strong reflection originating from the microscope slide.
We investigated a concentration range of 0–100 nM of Cy5.5-exendin-3 on CHL cells positive or neg-
ative for GLP1R. To discriminate between internalization and binding, the cells were incubated at either 
37 °C or 4 °C for 90 minutes. As shown in Fig. 3, complete internalization is observable down to 1 nM at 
Figure 1. Competition binding assay (IC50) of exendin-3 and Cy5.5-exendin-3 on CHL-GLP1R cells. 
111In-DTPA-exendin-3 was used as tracer. The sample with the highest binding percentage was set at 100%.
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37 °C whereas only a membrane staining is seen at 4 °C. In both cases, no signal is detectable in the CHL 
negative control. As an additional control we used a conventional confocal fluorescence microscope, 
which confirmed our findings.
Determination of Cy5.5-exendin-3 dose for a specific islet detection. To determine the min-
imum dose required for in vivo tracer detection of a fluorescence labeled tracer, three different doses 
of Cy5.5-exendin-3 (0.1, 1 and 14 μ g per mouse that is 2.6, 26.3 and 391.7 μ g/kg) were investigated. No 
fluorescent signal inside the islets could be detected 4 hours after the intravenous injection of 0.1 μ g of 
Cy5.5-exendin-3. Only in rare cases (< 5%) a weak fluorescence appeared at the limit of observation. 
Conversely both at 1 μ g and 14 μ g doses, the tracer accumulates only inside the islet 4 hours after injec-
tion (Fig. 4a). Although the fluorescence intensity of islets in mice injected with 14 μ g was stronger than 
at 1 μ g of Cy5.5-exendin-3 (Fig. 4b), the background signal in the exocrine pancreas was higher at 14 μ g 
than at 1 μ g of Cy5.5-exendin-3 (Fig. 4c), with a dot-like staining in the exocrine pancreas (Fig. 4a). In 
addition while right after injection of a 14 μ g tracer dose, a fluorescent signal appeared in the pancreas 
vasculature, at an intermediate dose of 1 μ g of Cy5.5-exendin-3, no fluorescent signal was observed in 
the vasculature but a strong fluorescent signal appeared inside the islets right after injection (Fig. S1).
A dose of 1 μ g of Cy5.5-exendin-3 is considered to be optimal based on our quantitative analysis. 
Firstly, the ratio (mean endocrine/mean exocrine fluorescence intensity) was ~6 for a 1 μ g dose and 
decreases to ~4 for a 14 μ g dose. Secondly, this finding is supported by the fact that the fluorescence 
signal with 1 μ g dose was well observable at 4 hours (Fig. 4b) after injection and that the signal in the exo-
crine pancreas was as low as in the control animals (Fig. 4c). In addition, we investigated whether there 
was a correlation between islets depth localization or its volume. However, no correlation could be found 
(Fig. S2). No fluorescent response was measured 4 hours after injection of a blocking solution of 100 μ g 
of unlabeled exendin-3 (Fig. 4a,b), confirming the specificity of Cy5.5-exendin-3 for islets of Langerhans.
Ex vivo organ analysis after in vivo imaging reveals the specificity of Cy5.5-exendin-3 for 
beta-cells. To further investigate the specificity of Cy5.5-exendin-3, the pancreata of mice injected 
with 14 μ g of Cy5.5-exendin-3 or only with PBS were sectioned and stained for insulin, glucagon and 
e-cadherin (Fig.  5a,b) and further analyzed by confocal fluorescence microscopy. This shows that the 
signal of Cy5.5-exendin-3 is co-localized with the insulin staining and is clearly internalized in beta-cells 
whereas alpha-cells did not internalize the tracer. No Cy5.5 signal was observed in the control mice 
injected only with PBS.
We performed an ex vivo study based on fluorescence imaging for establishing the biodistribution 
in several organs (heart, lung, duodenum, large intestine, stomach, kidney, spleen and liver). After dis-
section, a specific Cy5.5-fluorescent signal in the islets is still observable (Fig.  5c). Among the organs 
investigated, only the kidneys showed a strong fluorescent response (Fig. 5c) about 2 times higher than 
the signal observed in the islets (Fig. S3), which might cause difficulties for PET/SPECT imaging. In our 
OCM-fluorescence platform the kidneys and the pancreas are clearly distinguishable: no crosstalk was 
observed during the in vivo assessment.
Figure 2. Schematic layout of the dual systems. The dark-field effect is obtained by adding an annular 
mask (i) in the illumination and a pupil mask (ii) in the detection arm.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:10385 | DOi: 10.1038/srep10385
Cy5.5-exendin-3 targets islets within minutes and is stably detected for hours. We monitored 
the accumulation of the tracer over time in different islets (Fig. 6). No fluorescent signal was detected 
in islets prior to the ligand injection. Right after injection of the ligand, a signal was visible in the islets 
and remained stable over 4 hours. Moving red blood cells cause dynamic light scattering, which can 
be used by OCM for imaging of the pancreas vasculature28. This enables a parallel visualization of the 
tracer, the islet structure and its vasculature with a temporal resolution of ~20 μ s per depth-profile. The 
full 3D volume (512 × 512 × 512 voxel) is imaged in less than 10 seconds for structure and in less than 
1 minute for vascularization. The islet vascularization was unaltered after a 4 hour imaging session, which 
is crucial for a proper delivery of the ligand in the islets. Neither the surgical procedure (the pancreas of 
mice is exteriorized during the imaging session) nor the imaging is disturbing the blood supply in the 
islets and in the pancreas.
Discussion
The identification of beta-cells specific tracers and the characterization of the dose and dynamics of 
tracer accumulation are mandatory steps on the road towards human noninvasive beta-cell imaging. In 
this paper, we developed and validated an imaging platform well suited for the task of beta-cell tracer 
assessment. As a proof of principle we addressed the specificity of exendin-3 by in vitro imaging of cells 
Figure 3. In vitro experiments on CHL- hGLP1R cells. Cell imaging with the OCM/fluorescence platform 
after 90 min of incubation with different concentrations of Cy5.5-exendin-3 (0-100 nM) with CHL positive or 
negative for hGLP1R. Scale bar: 20 μ m.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:10385 | DOi: 10.1038/srep10385
expressing GLP1R and by in vivo imaging of pancreatic islets. Using this OCM platform, we demon-
strated that: (1) Cy5.5-exendin-3 is internalized in vitro by CHL cells expressing GLP1R; (2) in vivo for 
fluorescence labeled tracer investigations a dose as low as 1 μ g of the tracer is sufficient to be optically 
detected and quantified inside islets with a sufficient signal ratio discriminating well endocrine and exo-
crine tissue; (3) in vivo the tracer is specifically internalized as confirmed by blocking experiments with 
an excess of unlabeled exendin-3; (4) the discrimination of pancreatic islets by the fluorescent tracer is 
obtained already few minutes after injection and is observable for at least 4 hours. Last but not least, we 
showed that Cy5.5-exendin-3 is internalized by beta-cells but not by alpha-cells. In contrast to what was 
suggested by Reiner et al.29, we show that exendin-3 conjugated with Cy5.5 at the C-terminus lysine in 
position 40 specifically and efficiently accumulates in CHL cells expressing GLP1R and in the beta-cells 
in vivo.
Compared to classical optical fluorescence microscopy applied to image islets of Langerhans, our 
OCM platform offers several essential advantages: first, 3-dimensional OCM imaging requires only two 
lateral scans, resulting in a faster acquisition speed; second, no genetically modified mice to image islets 
of Langerhans are needed; and third, no injection of an external agent is needed to visualize the pancreas 
vascularization. However, to access the pancreas, a laparotomy and exteriorization of the pancreas are 
still required, as it is the case for any optical imaging method. A high beta-cell tracer detection requires 
Figure 4. Evaluation of different doses of Cy5.5-exendin-3 in vivo. (a) Representative images of the 
fluorescence signal and the corresponding xfOCM images 4 hours after injection of different doses of 
Cy5.5-exendin-3. Scale bar: 200 μ m. (b,c) Quantification of fluorescence islet intensity (b) and exocrine 
fluorescence intensity (c) 4 hours after injection of different doses of Cy5.5-exendin-3 (0.1, 1, 14 μ g), control 
(ctrl) and blocking (block.).* p < 10−4, ** p < 10−5, Mann-Whitney non-parametric U-test.
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good delivery and therefore demands a well perfused organ. The label-free imaging of the vascularization 
during the whole imaging session proved to be an essential asset for the assessment of tracer dynamics 
and accumulation. The artifacts visible in some vascularization images in Fig. 6 could be removed by a 
better stabilization of the pancreas, which remains an experimentally difficult endeavor for small animal 
imaging. A potential alternative could be the acquisition of additional transversal scan lines to better 
identify bulk intensity shifts30 and to discard them.
To assess the specificity of a potential tracer in vivo, optical approaches are needed to resolve individ-
ual islets and compare their intensity to other neighboring tissues. While islets can be discriminated due 
their intrinsic higher scattering signal in OCM, a fluorophore is necessary to detect the tracer. This can 
sometimes modify the binding properties of tracers, a limitation of the technique also shared by confocal 
Figure 5. Internalization of Cy5.5-exendin-3. (a,b) Representative sections showing the internalization 
of the tracer specifically in beta-cells (a) and not in alpha-cells (b). E-cadherin staining is shown in green. 
Scale bar: 20 μ m. (c) Ex vivo signal of the tracer is found in pancreatic islet and in the kidneys. The strong 
fluorescent intensity in the kidney requires using a pinhole to reject out of focus fluorescence. Scale bar: 
200 μ m.
Figure 6. Dynamics of the tracer in vivo. (a) Fluorescence signal detected over time after injection of 1 μ g 
of Cy5.5-exendin-3. (b) xfOCM (virtual structural section and maximum projection of vascularization) 
with fluorescence images at different time points indicated with a star symbol in a. Depth is color-coded 
in micrometers. Stripes in the vascularization images are due to residual pancreas movements. Scale bar: 
200 μ m.
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imaging and in general by other techniques offering such resolution in space and time. However, the 
speed of the technique allows to perform live imaging and quantifications of multiple islets in parallel. 
Previous assessments of dynamics by confocal microscopy have focused on one islet per mouse, which 
does not enable to assess the variation in signal3. We reveal that there is a range of responses, some islets 
being 3 fold stronger, but all islets reaching a plateau of signal in less than 15 min. This variability is 
averaged in PET/SPECT where the signal results from an integrated signal over multiple islets at different 
depths. The temporal signal over individual islets is however remarkably stable at the plateau, similar to 
confocal imaging3, with little variations due to breathing, heartbeat and peristaltic movements.
Since fluorescence detection is less sensitive than radioactivity detection, we expect differences in 
the required doses to detect a signal when fluorescence microscopy is used compared to PET/SPECT 
modalities. Our dose escalation study allows a better understanding of the differences in dosing between 
fluorescent tracers3,24 and radio-tracers15,25. We confirmed that a fluorescence signal is detectable both at 
14 μ g and 1 μ g similarly to other studies based on fluorescence detection of the tracer3,24. Of note, the 1 μ g 
dose is lower than the doses previously used for confocal microscopy in mouse (2–8 nmol/10–40 μ g per 
animal) but higher than the pharmacologic doses administered in human (5 μ g Exenatid per injection). 
In human imaging, the greater sensitivity of PET will enable to use lower doses a PET/SPECT imaging 
in mouse only requires around 0.1 μ g per animal16,25. At this dose, no signal is detected in fluorescence, 
however, similarly to what is observed in PET/SPECT we observed that increased doses result in a 
decrease of the relative uptake: a 14 μ g dose results in a lower target to background when compared to a 
dose of 1 μ g of Cy5.5-exendin-3. It is likely that at 14 μ g, we increase the background. In agreement with 
the biodistribution observed in PET/SPECT a high kidney retention of the tracer was detected.
The presented imaging technology provides a rapid assessment of tracer characteristics in vivo com-
plementing the tedious classical ex vivo procedures based on elaborate single time point biodistribution, 
autoradiography and immunohistochemistry experiments. Our optical imaging platform provides the 
basis for an efficient and exact in vivo dynamic characterization of beta-cell tracer close to the cellular 
level. Thereby, it offers the possibility to simplify the initial screening to determine whether a potential 
tracer is specific for beta-cells. Nevertheless, since the tracer detection relies on fluorescence, studies 
using PET/SPECT to image radio-labeled tracer injected in small rodents are required to determine the 
suitable dose for clinical imaging. Furthermore, the intrinsic contrast of islets and their vascularization 
opens the possibility to perform a label-free study during diabetes progression.
In conclusion, this dual-modality imaging allows in vivo monitoring of islet structure, vascularization 
and tracer uptake for pancreas imaging. As shown, our approach is a preclinical and complementary 
imaging method to MRI/PET/SPECT to characterize beta-cell tracers in mice when the tracer is large 
enough to be coupled to fluorescent probes.
Materials and Methods
Animals and pancreas imaging with xfOCM. All animal experiments were carried out in strict 
accordance with the recommendations of the federal and local ethical guidelines. The protocols were 
approved by the local regulatory body of the Canton Vaud, Switzerland (SCAV, authorization 2050). For 
these investigations, ICR female adult mice were obtained from the Harlan laboratories and underwent 
laparotomy procedure as previously described8. For imaging longer than 30 minutes, the anesthesia was 
prolonged with 1% isoflurane mixed with oxygen. During the imaging session the mice are kept on a 
heating stage. The animals were imaged using the xfOCM/confocal fluorescence (Fig. 2) dual system to 
image the islets (OCM-mode) and the Cy5.5 tracer (fluorescence mode).
Cell culture and imaging with dfOCM. Chinese hamster lung (CHL) cells stably transfected with 
the human GLP1-receptor (CHL-hGLP1R)31 are a donation from Martin Béhé (PSI, Switzerland). 
CHL-hGLP1R were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) GlutaMax (Gibco, 
Invitrogen, catalog 61965) supplemented with 10% heat-inactivated fetal calf serum (vol/vol), 100 units/ml 
penicillin and 100 μ g/ml streptomycin, 50 mg/ml geneticin (G418) sulphate solution (PAA laboratories 
GmbH, GE Healthcare), 1 mM sodium pyruvate, and 0.1 mM Non-Essential Amino Acids (NEAA), in a 
humidified 5% CO2 atmosphere at 37 °C. hGLP1R negative CHL cells were grown in the same medium 
but without geneticin. The cells were harvested by trypsinization with trypsin/EDTA. CHL-hGLP1R 
and CHL negative cells were seeded on μ -Dish 35 mm (Ibidi) and cultured overnight. The cells were 
washed three times with Krebs buffer (NaCl 7.795 g/L, KCl 0.354 g/L, KH2PO4 0.162 g/L, MgS4H2O 
0.293 g/L, CaCl2H2O 0.374 g/L, NaHCO3 0.424 g/L, Hepes 2.39 g/L) and incubated at 37 °C or 4 °C with 
Cy5.5-exendin-3 (0–100 nM) for 90 min in Krebs buffer with 3.9 mM glucose. Following incubation, cells 
were washed three times with Krebs buffer and put at 4 °C before imaging. Cells were imaged using the 
dfOCM/confocal fluorescence dual system (Fig.  2) to match the signals originating from cells and the 
Cy5.5-exendin-3 tracer.
Conjugation of Exendin-3 with fluorophore and radionuclide and IC50 determination. 111InCl3 
was obtained from Covidien (Petten, The Netherlands) and (DTPA-) exendin-3 was purchased from 
Peptide Specialty Laboratories (PSL, Heidelberg, Germany). Cy5.5 Mono NHS Ester was purchased from 
Amersham (GE Healthcare, Buckinghamshire, UK) and conjugated to exendin-3 by PSL. Both DTPA 
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and CyTM5.5 Mono NHS Ester were conjugated to the ε-amino group of the Lysine residue at position 
40. DTPA-exendin-3 was radiolabeled with 111InCl3 as described previously25.
The 50% inhibitory concentrations (IC50) of exendin-3 and Cy5.5-exendin-3 were determined using 
CHL-GLP1R cells, grown to confluence in 6-wells plates. Concentrations of the unlabeled exendin-3 
and Cy5.5-exendin-3 ranging from 0.1 to 300 nmol in DMEM-GlutaMax with 0.5% (w/v) bovine serum 
albumin (BSA) (n = 3) were added to the cells together with 50,000 cpm 111In-DTPA-exendin-3. The cells 
were incubated for 4 h on ice, washed twice with DMEM-GlutaMax with 0.5% BSA and harvested using 
1 ml 0.1 M NaOH. The radioactivity associated with the cells was measured in a well-type gamma coun-
ter (Wallac 1480-Wizard, Perkin-Elmer, Boston, MA, USA). The IC50 values were calculated by one-site 
competition analysis with Graphpad Prism (version 5.03, GraphPad Software, San Diego California 
USA). An unpaired t-test was used for significance determination with a p-value below 0.05 considered 
as significant.
In vivo evaluation of different doses, blocking experiments, time-lapse imaging and image 
analysis. Mice were injected intravenously in the tail vein with either 0.1 μ g (2.6 μ g/kg, 0.5 nmol/kg, 
n = 4 mice, 65 islets analyzed in total), 1 μ g (26.3 μ g/kg, 5.5 nmol/kg, n = 5 mice, 68 islets analyzed in 
total) or 14 μ g (391.7 μ g/kg, 82.2 nmol/kg, n = 4 mice, 34 islets analyzed in total) of Cy5.5-exendin-3 in 
200 μ l of PBS and imaged 4 hours after ligand injection. Control mice (n = 5 mice, 24 islets analyzed 
in total) were injected with PBS only. For blocking experiments, 1 μ g of Cy5.5-exendin-3 and 100 μ g 
of exendin-3 (2.8 mg/kg, 0.6 μ mol/kg) in 200 μ l of PBS were injected intravenously in the tail vein and 
imaged 4 hours later (n = 4 mice, 56 islets analyzed in total). For time-lapse imaging, mice were injected 
intravenously with 1 μ g of Cy5.5-exendin-3 in 200 μ l of PBS and imaged for up to 4 hours (n = 4 mice, 
9 islets analyzed in total). Quantification of the fluorescence signal of Cy5.5-exendin-3 was performed 
on images taken with an open pinhole. The median fluorescent intensity of the pixels belonging to an 
islet was quantified in a post processing step by a semi-automatic segmentation of the fluorescent signal 
overlapping the OCM signal of islet. For time-lapse imaging, the time intensity curve was smoothed with 
an averaging filter of three, i.e. each point represents the averaging of 3 consecutive points.
OCM instruments for small animal and cell imaging. 
xfOCM  All in vivo imaging was performed with our xfOCM instrument11,26 equipped with a Zeiss 
Neofluar objective (10x; NA 0.3, Carl Zeiss) with a lateral resolution of 1.3 μ m and a depth of field of 
~400 μ m. The illumination power on the pancreas was around 5 mW to acquire a full profile over the 
extended depth. Imaging the pancreas vascularization is based on a specific scanning protocol32 and a 
phase variance algorithm10. This method uses a specific scanning protocol where each line (B-scan) is 
scanned several times. For our measurements, 8 B-scans were taken at 50 kHz (18 μ s integration time 
per depth-profile). The circular variance of temporal phase changes was calculated to extract the vascu-
larization. To improve the contrast, the circular variance was averaged over a window of 8 pixels in the 
axial direction.
dfOCM  The dark field OCM (dfOCM)27 is used for cell imaging. dfOCM suppresses all specular 
reflections which originate from the sample slide. For in vitro cell imaging, the added darkfield mask 
placed in a conjugated plane to the back focal plane of the objective increases the contrast for cell meas-
urements substantially. Our dfOCM instrument contains a plan apochromat immersion objective (25x; 
NA = 0.8, Carl Zeiss) resulting in a 900 nm lateral resolution and an the work isotropic is not correctly 
used here since we have a lateral resolution of 900 nm and an axial resolution of 3 μ m. It is therefore 
better to remove it. 3 μ m axial resolution over a field depth of 50 μ m.
Both instruments have a fluorescence channel using the same scanning unit for a simultaneous acqui-
sition of the fluorescence and the OCM signal. For suppressing any crosstalk between the OCM and 
fluorescence channel detection, a high pass filter (HQ720lp, Chroma Technology Corp.) is placed in the 
illumination arm. For the fluorescence excitation, a tunable supercontinuum laser was used (Koheras 
SuperK Extreme, NKT Photonics). A dichroic mirror (720dcxr, Chroma Technology Corp. and a KG1 
Schott infrared absorber) in combination with a complementary excitation filter (HQ680/35m, Chroma 
Technology Corp.) rejects the NIR spectrum and enhances the SNR for the fluorescence detection. 
Excitation and emission light was separated by a dichroic mirror and excitation filter (z647RDC, Chroma 
Technology Corp. and Z635/10x, Chroma Technology Corp.). The fluorescence signal was detected by 
an avalanche photodiode (SPCM-AQR-14-FC; PerkinElmer) and digitized with a NIDAQ card (National 
instruments).
Immunofluorescence. At the end of the imaging session, mice were intraperitoneally injected with 
1 ml/kg body weight of a solution of pentobarbital (150 mg/ml). The deeply anesthetized animals were 
transcardially perfused for 2 minutes with PBS and for 8 minutes with 4% paraformaldehyde (PFA) solu-
tion. The pancreas was further fixed for 1 day at 4 °C in 4% PFA, prior to an overnight incubation 
in a 30% (wt/vol.) sucrose solution in PBS at 4 °C. The pancreas was embedded in Optimal Cutting 
Temperature compound and frozen in isopentane cooled with dry ice. 8 μ m cryosections were prepared 
for staining. The sections were permeabilized 10 minutes with PBS-TritonX100 0.25% and blocked in 
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10% fetal bovine serum for 30 minutes at room temperature. Incubation with primary antibodies (guinea 
pig insulin 1:50 Dako, rabbit glucagon 1:200 Cell Signaling, rat e-cadherin 1:100 Takara Bio) was per-
formed at 4  °C overnight in a humid chamber. Secondary antibodies were incubated 45 minutes at room 
temperature. The sections were further stained with Dapi (1:10000) for 10 minutes at room temperature 
and mounted with DABCO mounting medium. These immunostained samples were inspected with a 
ZEISS LSM 710 microscope equipped with a 63x oil Plan-Apochromat objective (NA = 1.4).
Statistical analysis. Data are presented as mean with standard deviation.
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